Scotiabank Downgrades Blueprint Medicines (NASDAQ:BPMC) to Hold
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) was downgraded by analysts at Scotiabank from a “strong-buy” rating to a “hold” rating in a report released on Monday, MarketBeat Ratings reports. They currently have a $135.00 price objective on the biotechnology company’s stock. Scotiabank’s target price would suggest a potential upside of 5.80% from the stock’s […]
More Stories
The Metrics Behind Game Design: How Data Shapes the Way We Play
Game designing is an art. Before a gamer gets to enjoy the characters and the narrative, it is essential for...
What Happens When Your Advice Backfires? The Risk of Being ‘Almost Right’
There’s a strange kind of confidence that creeps in when you’ve built your career on giving advice. If there’s anything...
One Piece Season 2: Release Date, Trailer, Cast, and Other Announcements
One Piece season 2 is expected to be released in 2026, as the shooting was completed in early 2025. For...
Perplexity AI Wants to Buy Google Chrome for $34.5 Billion!
A young artificial intelligence company called Perplexity AI has surprised the tech world by offering $34.5 billion to buy Google...
White House Orders Review of Smithsonian Exhibits Ahead of Nation’s 250th Birthday
By Victoria Friedman The White House on Tuesday ordered an internal review of selected Smithsonian museums and exhibitions to ensure...
Mexico Extradites 26 Alleged Cartel Members to US
By Aldgra Fredly Mexico extradited 26 alleged cartel members to the United States on Aug. 12, including high-ranking members of...